BACKGROUND: Markers of Epstein-Barr virus (EBV) infection include anti-viral capsid antigen (VCA) immunoglobulin (Ig) G. High anti-VCA titers are associated with EBV-related lymphoproliferation, such as Burkitt lymphoma (BL) and Hodgkin lymphoma (HL). METHODS: Intrafamilial correlations of anti-VCA IgG levels were studied in 3 settings: 127 families recruited through patients with HL in France (population A), 31 families recruited through patients with BL in Uganda (population B), and 74 large families from a general population in Cameroon (population C). Titers were determined by enzyme-linked immunosorbent assay (populations A and C) or by immunofluorescence analysis (population B). RESULTS: In populations A and B, the anti-VCA IgG titers of the relatives of patients with HL or BL increased significantly (P = .01 and P < .001, respectively) with those of the index case patient. In all 3 populations, anti-VCA IgG titers were significantly correlated (P < .001 for A, P = .002 for B, and P < .001 for C) between genetically related individuals (father-offspring, mother-offspring, and sibling-sibling) but not between spouses. Similar results were obtained for population A after adjustment for total IgG levels. In all cases, the pattern of correlations was consistent with a polygenic model, with heritability ranging from 0.32 to 0.48. CONCLUSION: These results provide evidence for the genetic control of anti-VCA IgG titers and pave the way for identification of the loci involved.
BACKGROUND: Markers of Epstein-Barr virus (EBV) infection include anti-viral capsid antigen (VCA) immunoglobulin (Ig) G. High anti-VCA titers are associated with EBV-related lymphoproliferation, such as Burkitt lymphoma (BL) and Hodgkin lymphoma (HL). METHODS: Intrafamilial correlations of anti-VCA IgG levels were studied in 3 settings: 127 families recruited through patients with HL in France (population A), 31 families recruited through patients with BL in Uganda (population B), and 74 large families from a general population in Cameroon (population C). Titers were determined by enzyme-linked immunosorbent assay (populations A and C) or by immunofluorescence analysis (population B). RESULTS: In populations A and B, the anti-VCA IgG titers of the relatives of patients with HL or BL increased significantly (P = .01 and P < .001, respectively) with those of the index case patient. In all 3 populations, anti-VCA IgG titers were significantly correlated (P < .001 for A, P = .002 for B, and P < .001 for C) between genetically related individuals (father-offspring, mother-offspring, and sibling-sibling) but not between spouses. Similar results were obtained for population A after adjustment for total IgG levels. In all cases, the pattern of correlations was consistent with a polygenic model, with heritability ranging from 0.32 to 0.48. CONCLUSION: These results provide evidence for the genetic control of anti-VCA IgG titers and pave the way for identification of the loci involved.
Authors: Rohina Rubicz; Charles T Leach; Ellen Kraig; Nikhil V Dhurandhar; Ravindranath Duggirala; John Blangero; Robert Yolken; Harald H H Göring Journal: Hum Hered Date: 2011-10-11 Impact factor: 0.444
Authors: Rohina Rubicz; Robert Yolken; Eugene Drigalenko; Melanie A Carless; Thomas D Dyer; Jack Kent; Joanne E Curran; Matthew P Johnson; Shelley A Cole; Sharon P Fowler; Rector Arya; Sobha Puppala; Laura Almasy; Eric K Moses; Ellen Kraig; Ravindranath Duggirala; John Blangero; Charles T Leach; Harald H H Göring Journal: Eur J Hum Genet Date: 2015-03-11 Impact factor: 4.246
Authors: Geno Guerra; Linda Kachuri; George Wendt; Helen M Hansen; Steven J Mack; Annette M Molinaro; Terri Rice; Paige Bracci; John K Wiencke; Nori Kasahara; Jeanette E Eckel-Passow; Robert B Jenkins; Margaret Wrensch; Stephen S Francis Journal: Am J Hum Genet Date: 2022-05-11 Impact factor: 11.043
Authors: Charlotte J Houldcroft; Velislava Petrova; Jimmy Z Liu; Dan Frampton; Carl A Anderson; Astrid Gall; Paul Kellam Journal: PLoS One Date: 2014-10-07 Impact factor: 3.240
Authors: Rohina Rubicz; Robert Yolken; Eugene Drigalenko; Melanie A Carless; Thomas D Dyer; Lara Bauman; Phillip E Melton; Jack W Kent; John B Harley; Joanne E Curran; Matthew P Johnson; Shelley A Cole; Laura Almasy; Eric K Moses; Nikhil V Dhurandhar; Ellen Kraig; John Blangero; Charles T Leach; Harald H H Göring Journal: PLoS Genet Date: 2013-01-10 Impact factor: 5.917
Authors: N Sallah; T Carstensen; K Wakeham; R Bagni; N Labo; M O Pollard; D Gurdasani; K Ekoru; C Pomilla; E H Young; S Fatumo; G Asiki; A Kamali; M Sandhu; P Kellam; D Whitby; I Barroso; R Newton Journal: Glob Health Epidemiol Genom Date: 2017-11-27
Authors: Robert Newton; Denise Whitby; Inês Barroso; Neneh Sallah; Wendell Miley; Nazzarena Labo; Tommy Carstensen; Segun Fatumo; Deepti Gurdasani; Martin O Pollard; Alexander T Dilthey; Alexander J Mentzer; Vickie Marshall; Elena M Cornejo Castro; Cristina Pomilla; Elizabeth H Young; Gershim Asiki; Martin L Hibberd; Manjinder Sandhu; Paul Kellam Journal: Nat Commun Date: 2020-07-31 Impact factor: 14.919
Authors: Linda Kachuri; Stephen S Francis; Maike L Morrison; George A Wendt; Yohan Bossé; Taylor B Cavazos; Sara R Rashkin; Elad Ziv; John S Witte Journal: Genome Med Date: 2020-10-27 Impact factor: 15.266